Abstract Search

ba0007p71 | (1) | ICCBH2019

Necessity of high dose and prolonged duration denosumab post stem cell transplant for TNFRSF11A osteoclast-poor autosomal recessive osteopetrosis

Taylor-Miller Tashunka , Doss Hemalatha , Weerdenburg Heather , Whiting Sam , Sivaprakasam Ponni , Gassass Adam , Smithson Sarah F , Steward Colin G , Burren Christine P

Background: Hypercalcaemia is a risk following stem cell transplant (SCT) for all types of autosomal recessive osteopetrosis (ARO) due to restored osteoclast differentiation. This can be particularly severe in the osteoclast-poor (OP) form involving the tumour necrosis factor receptor superfamily 11A (TNFRSF11A) gene, encoding RANK. Denosumab, a monoclonal antibody blocking RANK activation, has been described for refractory post-SCT hypercalcaemia in two cases. Our case adds n...

0 shares

Bone Abstracts

Necessity of high dose and prolonged duration denosumab post stem cell transplant for TNFRSF11A osteoclast-poor autosomal recessive osteopetrosis

BiosciAbstracts